Intravitreal bevacizumab for macular edema secondary to central retinal vein occlusion may induce resolution of macular edema. However, the possibility of a rebound macular edema thicker than at the initial presentation after intravitreal bevacizumab injections has been reported. A case of dramatic deterioration of central retinal vein condition with hemorrhagic macular infarction 3 weeks after intravitreal injection of bevacizumab is presented.
Hemorrhagic Macular Infarction After Intravitreal Bevacizumab for Central Retinal Vein Occlusion / Furino, C; Boscia, Francesco; Cardascia, N; Alessio, G; Sborgia, C.. - In: OPHTHALMIC SURGERY, LASERS & IMAGING. - ISSN 1542-8877. - MAR 9:1-2(2010). [10.3928/15428877-20100215-57.]
Hemorrhagic Macular Infarction After Intravitreal Bevacizumab for Central Retinal Vein Occlusion.
BOSCIA, Francesco;
2010-01-01
Abstract
Intravitreal bevacizumab for macular edema secondary to central retinal vein occlusion may induce resolution of macular edema. However, the possibility of a rebound macular edema thicker than at the initial presentation after intravitreal bevacizumab injections has been reported. A case of dramatic deterioration of central retinal vein condition with hemorrhagic macular infarction 3 weeks after intravitreal injection of bevacizumab is presented.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
